Peter McWilliams, Ph.D.
Chief Executive Officer
Dr. McWilliams is the CEO of Glycomine. He was previously a Managing Director at Sanderling Ventures where he was responsible for its investment in Actimis Pharmaceuticals and, as CEO, led the company into the clinic and through to a successful exit via an acquisition by Boehringer Ingelheim. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in pre-clinical and clinical development including the anti-angiogenesis therapeutic, Avastin®. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Horacio Plotkin, M.D., F.A.A.P.
Chief Medical Officer
Dr. Horacio Plotkin has more than 30 years of experience in the rare diseases field, including 20 years of pediatric clinical experience and 10+ additional years of experience in drug development, having held positions at Genzyme, Enobia Pharma, Alexion Pharmaceuticals, Retrophin, Shire, PPD, Moderna and Selecta Biosciences. He is an Adjunct Associate Professor of Pediatrics and Orthopedic Surgery at the University of Nebraska School of Medicine and the founder and first Medical Director of the Pediatric Bone Diseases Program at Omaha Children’s Hospital. Dr. Plotkin earned his medical degree from the University of Buenos Aires School of Medicine. He completed a residency program in pediatrics, followed by four fellowships: pediatric endocrinology (J. P. Garrahan Pediatric Hospital, Buenos Aires), metabolic bone diseases (Metabolic Research Institute, Buenos Aires), endocrinology (Yale University School of Medicine, Connecticut) and pediatric metabolic bone diseases (Shriners Hospital for Children and Department of Surgery, McGill University, Montreal). Dr. Plotkin is a member of the scientific advisory board for several rare disease patient advocacy organizations and a member of the Advances in Therapeutics and Technology section at the American Academy of Pediatrics. He has authored eight chapters in medical textbooks and more than 50 scientific papers.
Geoffrey Hird, Ph.D.
VP of Pharmaceutical Development and CMC
Dr. Geoffrey Hird has more than 20 years of experience in all stages of pharmaceutical product development having held positions at Eisai, GSK, and Liquidia Technologies. In addition to working in industry, Geoff is also an Adjunct Associate Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His experience spans leading projects on new chemical entities, drug delivery technologies, life cycle management and innovative generics. Dr. Hird earned his B.S. in Chemistry from The College of William and Mary and a Ph.D. in Chemistry from Duke University where his thesis focused on the development of a novel liposomal drug delivery systems.
Lisa Koch-Hulle, RAC
VP, Regulatory Affairs
Lisa Koch-Hulle has more than 25 years of regulatory affairs experience across multiple therapeutic areas and all stages of drug development, with approximately 15 years at the senior management level. Prior to Glycomine, Ms. Koch-Hulle held the position of Vice President of Regulatory Affairs and Clinical Operations at Light Sciences Oncology, and prior to that held the same position at La Jolla Pharmaceutical Company. Ms. Koch-Hulle has also served as a regulatory consultant to the pharmaceutical industry. Ms. Koch-Hulle holds regulatory certifications in US, European, and Global regulatory affairs, and is a former Chair of the RAPS European Certification Committee.
Teppei Shirakura, Ph.D.
Scientific Director, Chemistry
Dr. Shirakura is a Biophysicist with expertise in the development of hydrogel nanoparticles for targeted and controlled drug release for cancer therapy, diagnosis, and imaging. He leads the design and synthesis of nanotechnology-based platforms for intracellular delivery of Glycomine’s therapies. Teppei obtained a B.S. in Biophysics from Iowa State University and a Ph.D. in Biophysics from University of Michigan.
Director, Clinical Operations
Prior to joining Glycomine, she held positions within Clinical Operations at Takeda Pharmaceuticals, Shire Human Genetic Therapies and Novartis Institute for Biomedical Research. She was most recently a Clinical Operations Program Lead at Takeda Pharmaceuticals managing multiple programs across therapeutic areas including Gastroenterology and Rare Diseases. She received a B.S. in Neuroscience from Brandeis University.